Literature DB >> 9001699

Opioid antagonists in the periaqueductal gray inhibit morphine and beta-endorphin analgesia elicited from the amygdala of rats.

Z W Pavlovic1, M L Cooper, R J Bodnar.   

Abstract

In addition to brainstem sites of action, analgesia can be elicited following amygdala microinjections of morphine and mu-selective opioid agonists. The present study examined whether opioid analgesia elicited by either morphine or beta-endorphin in the amygdala could be altered by either the general opioid antagonist, naltrexone, the mu-selective antagonist, beta-funaltrexamine (BFNA) or the delta 2 antagonist, naltrindole isothiocyanate (Ntii) in the periaqueductal gray (PAG). Both morphine (2.5-5 micrograms) and beta-endorphin (2.5-5 micrograms) microinjected into either the baso-lateral or central nuclei of the amygdala significantly increased tail-flick latencies and jump thresholds in rats. The increases were far more pronounced on the jump test than on the tail-flick test. Placements dorsal and medial to the amygdala were ineffective. Naltrexone (1-5 micrograms) in the PAG significantly reduced both morphine (tail-flick: 70-75%; jump: 60-81%) and beta-endorphin (tail-flick: 100%; jump: 93%) analgesia elicited from the amygdala, indicating that an opioid synapse in the PAG was integral for the full expression of analgesia elicited from the amygdala by both agonists. Both BFNA (68%) and Ntii (100%) in the PAG significantly reduced morphine, but not beta-endorphin analgesia in the amygdala on the tail-flick test. Ntii in the PAG was more effective in reducing morphine (60%) and beta-endorphin (79%) analgesia in the amygdala on the jump test than BFNA (15-24%). Opioid agonist-induced analgesia in the amygdala was unaffected by opioid antagonists administered into control misplacements in the lateral mesencephalon, and the small hyperalgesia elicited by opioid antagonists in the PAG could not account for the reductions in opioid agonist effects in the amygdala. These data indicate that PAG delta 2, and to a lesser degree, mu opioid receptors are necessary for the full expression of morphine and beta-endorphin analgesia elicited from the amygdala.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9001699     DOI: 10.1016/s0006-8993(96)00880-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

1.  Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization.

Authors:  Shoshana Eitan; Camron D Bryant; Nazli Saliminejad; Yu C Yang; Elroy Vojdani; Duane Keith; Roberto Polakiewicz; Christopher J Evans
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

2.  PAG mu opioid receptor activation underlies sex differences in morphine antinociception.

Authors:  Scott A Bernal; Michael M Morgan; Rebecca M Craft
Journal:  Behav Brain Res       Date:  2006-11-21       Impact factor: 3.332

3.  Functional interaction between medial thalamus and rostral anterior cingulate cortex in the suppression of pain affect.

Authors:  S E Harte; C A Spuz; G S Borszcz
Journal:  Neuroscience       Date:  2010-10-27       Impact factor: 3.590

Review 4.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

5.  A lateralized deficit in morphine antinociception after unilateral inactivation of the central amygdala.

Authors:  B H Manning
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

6.  Distinct pathways for norepinephrine- and opioid-triggered antinociception from the amygdala.

Authors:  J J Maire; L N Close; M M Heinricher; N R Selden
Journal:  Eur J Pain       Date:  2015-04-05       Impact factor: 3.931

7.  N-methyl-D-aspartate receptor agonism and antagonism within the amygdaloid central nucleus suppresses pain affect: differential contribution of the ventrolateral periaqueductal gray.

Authors:  Catherine A Spuz; Michelle L Tomaszycki; George S Borszcz
Journal:  J Pain       Date:  2014-09-23       Impact factor: 5.820

Review 8.  Endogenous opioid peptides in the descending pain modulatory circuit.

Authors:  Elena E Bagley; Susan L Ingram
Journal:  Neuropharmacology       Date:  2020-05-15       Impact factor: 5.250

9.  Contribution of the periaqueductal gray to the suppression of pain affect produced by administration of morphine into the intralaminar thalamus of rat.

Authors:  Elizabeth M Munn; Steven E Harte; Alexander Lagman; George S Borszcz
Journal:  J Pain       Date:  2009-02-23       Impact factor: 5.820

10.  Identification of candidate genes and gene networks specifically associated with analgesic tolerance to morphine.

Authors:  Jenica D Tapocik; Noah Letwin; Cheryl L Mayo; Bryan Frank; Troung Luu; Ovokeraye Achinike; Carrie House; Russell Williams; Greg I Elmer; Norman H Lee
Journal:  J Neurosci       Date:  2009-04-22       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.